Background The Thai phase 3 HIV vaccine trial RV 144 showed modest effi cacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not modify vaccine effi cacy. We did a post-hoc analysis of the trial's data to investigate behavioural risk and effi cacy every 6 months after vaccination.
Introduction
The results of the phase 3 Thai HIV vaccine trial RV 144 1 suggest that a vaccine to prevent acquisition of HIV infection is possible. 1 Although the effi cacy was modest and insuffi cient to warrant licensure, the study provided both insights and opportunities for future investigations into prevention of HIV acquisition. The investigators of the trial reported two salient, hypothesis-generating fi ndings: effi cacy seemed greatest in participants at lower risk for HIV infection compared with the study-defi ned high-risk participants, and effi cacy seemed maximum early after admin istration, but decreased with time.
By contrast with previous effi cacy trials for HIV vaccines, the investigators of RV 144 enrolled mainly heterosexual people from a population with low prevalence of HIV. 1 Most sexual encounters in RV 144 were unlikely to be associated with risk of HIV transmission. Few incident cases in the study were from well defi ned high-risk groups such as sex workers, homosexual and bisexual men, or injecting drug users. The study was not designed to assess risk-stratifi ed effi cacy rates and no signifi cant interaction between baseline risk and effi cacy was noted, 1 although estimated vaccine effi cacy was greater than 40% in the low-risk groups at baseline, and less than 5% in high-risk participants. In other diseases, suffi cient challenge doses can overwhelm vaccine-induced protective immune responses. 2 The modest success noted in RV 144 could be because of low viral challenge encountered in the study population.
Results of non-human-primate challenge studies with high-dose, intravenous simian immunodefi ciency virus (SIV) and pathogenic simian HIV have suggested that protection from infection is not feasible, but a favourable modifi cation of early viral burden and clinical outcome is achievable. 1 A notable outcome in RV 144 was the absence
This article is a U.S. government work, and is not subject to copyright in the United States. of an eff ect on viral load in vaccine recipients. 1 Most of these non-human-primate studies used intravenous or non-physiological, high-dose mucosal challenge doses of virus. Non-human-primate challenge studies 3, 4 with repeat, low-dose mucosal challenge with SIV after vaccination have shown protection from acquisition with no or variable eff ect on viral load or clinical outcome in animals with breakthrough infection. These fi ndings are consistent with the notion that available vaccines against SIV and simian HIV aff ord a reduction in acquisition risk in repeat, lowdose mucosal challenge experiments that more closely model human transmucosal risk. Taken together, these fi ndings also suggest that the immune responses associated with protection from infection are mostly distinct from those needed for reduction of viraemia and improved clinical outcome, and are similar to the results of a summary of data from human trials of breakthrough infections with the ALVAC-protein boost regimen and an SIV non-human-primate challenge study. [5] [6] [7] The RV 144 study was designed to acquire endpoints over 3·5 years after initial vaccination in more than 16 000 volunteers with 90% statistical power to address the acquisition objective of 50% effi cacy. This population size and extended follow-up was needed because of the ten-fold reduction in yearly HIV incidence in Thailand as a consequence of a vigorous public health campaign for prevention of HIV/AIDS. 8, 9 The trial was not designed to defi ne time-dependent eff ects. Nevertheless, the data suggest that effi cacy fell during the extended observation period, although this fi nding was not signifi cant. 1 We previously reported 1 that baseline behavioural risk characteristics were balanced by treatment group and associated with diff erent placebo group transmission rates ranging from 0·227 per 100 person-years in the low-risk group to 0·364 per 100 person-years in the high-risk group (p=0·005, adjusted for treatment). However, estimates of vaccine effi cacy were not signifi cantly diff erent when compared by baseline behavioural risk covariate or any other parameter assessed, including sex, age, and baseline partnership status. 1 We aimed to further explore, in a post-hoc analysis, the interaction of risk behaviour and effi cacy during the full course of the study and examine time-dependent estimates of effi cacy to guide the design of future effi cacy trials for HIV vaccines.
Methods

Study design and participants
The main study methods and results including the screening, enrolment, and retention data by group have been published previously. 1 Briefl y, RV 144 was a randomised, multicentre, double-blind, placebocontrolled effi cacy trial testing the combination of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prevent HIV infection or reduce setpoint viral load. Male and female volunteers aged 18-30 years were recruited from the community irrespective of HIV risk through a separate screening protocol. Volunteers received a trial information briefi ng and gave written informed consent for participation in the screening protocol. HIV testing was done, and a follow-up visit at one of the eight clinical research sites was scheduled for 2-3 weeks later.
Procedures
Volunteers returned for follow-up after the screening visit, were informed of their HIV test results and, if seronegative, written informed consent for participation in the trial was obtained and vaccinations begun. The protocol was reviewed and approved by the Ethical Committees of the Ministry of Public Health, the Royal Thai Army, Mahidol University, and the Human Subjects Research Review Board of the US Army Medical Research and Materiel Command.
Vaccinations were given over 24 weeks. The ALVAC-HIV (vCP1521) or placebo prime was given in the left arm at weeks 0, 4, 12, and 24. Boosting with AIDSVAX B/E or placebo was given in the right arm at weeks 12 and 24. The volunteers were followed up with HIV testing (with appropriate counselling before and after the test) every 6 months for 3 years. Plasma samples for HIV-1 diagnostics were taken at 0 weeks and 24 weeks, and every 6 months during the follow-up phase. Research staff provided education about reduction of risky behaviours during each vaccination and post-test counselling visit. The scheme for clinical trial conduct from screening to treatment and analysis allocation is published elsewhere. 1 Assessment of HIV risk behaviour within the preceding 6 months was done at baseline, 24 weeks, and each 6 month follow-up visit with a self-administered questionnaire. Volunteers had to classify whether their everyday behaviour placed them at risk for HIV infection. The questionnaire then identifi ed specifi c risk behaviours for HIV acquisition. At each visit, participants were classifi ed as high risk if in the past 6 months they met one of the following criteria: reported that their behaviour placed them at risk for HIV; had shared needles when injecting drugs; had two or more sexual partners; had an HIV-positive sexual partner; had not used a condom during their last sexual contact (if this sexual contact had been within the past 6 months) with a sex worker, casual partner, same-sex partner, drug-injecting partner, or partner with several partners; had symptoms of a sexually transmitted infection; had used injecting drugs while in prison; or were employed at baseline as prostitutes or in the restaurants and bars where commercial sex transactions were commonly organised. Volunteers were deemed low risk if, in the previous 6 months, they perceived their behaviour did not place them at risk of HIV infection; had no or one sexual partner and no sex with sex workers, casual partners, same-sex partners, HIV-positive partners, drug-injecting partners, or partners with many partners; or had not been in prison and reported no symptoms of sexually transmitted infections. The moderate risk category contained people with neither low nor high risk-eg, an individual with a single partner who was a sex worker, injecting drug user, same-sex partner, or casual partner, but had used condoms at the last sexual encounter. Individuals who did not answer an item on the risk questionnaire but were otherwise inconsistent with the high-risk profi le were classifi ed as moderate risk. The risk score categories were devised from baseline responses through use of combined-group infection results in a blinded fashion. The terms high, moderate, and low are relative to each other within this population and do not equate to typical defi nitions in high-risk cohorts.
Statistical analysis
Seven volunteers with prevalent infection at baseline were excluded, and the modifi ed intention-to-treat population was used for the analyses (16 395). To account for missing data because of people leaving the study early, we estimated the proportion of individuals with identifi ed risk characteristics with the product-limit survival method. Multiple proportional hazards regression models with treatment and time-varying risk covariates were analysed. Effi cacy was higher in participants reporting low or medium risk at baseline than in those reporting high-risk behaviours at baseline. Taking all reported behaviours over time into consideration, participants with risk classifi ed as high or ever increasing by the time-varying covariate model were compared with those who had low or medium risk at entry and throughout the study. Vaccine effi cacy was also assessed for maximum degree of risk reported during the study and risk degree reported in the study before seroconversion. Vaccine effi cacy estimates from the Kaplan-Meier infection estimates were calculated every 6 months. A non-parametric estimate of the relative hazard function and confi dence intervals were calculated. 10 Descriptive statistics were generated and pointwise Wilcoxon tests of viral load were done. Twotailed p values are reported. Table 2 : Cumulative vaccine effi cacy* at 6 month intervals for the modifi ed intention-to-treat population determined from Kaplan-Meier infection rates study and had fi nal responsibility for the decision to submit for publication (each of the partners had the opportunity to comment).
Results
The proportion of participants classifi ed as low risk increased, and the numbers in the medium and high risk categories fell, during the fi rst 52 weeks of the study, and remained stable thereafter (fi gure 1). The distribution of risk for both overall category and individual risk items (data not shown) between treatment groups was balanced. Condom use was stable during the study for all partner types. The proportions of men and women in each risk category were similar (data not shown). Participants could skip a question or report "I don't know or I am not sure", and these response rates fell as the study progressed. For example, 1218 of 16 373 (7·4%) respondents declined to answer the question about injecting drug use with needle sharing at study entry, but at the end of the study 303 of 14 794 (2·0%) declined to answer, with a small corresponding increase in reported rates both affi rming and denying this behaviour over time. 105 (34·7%) of the participants who did not answer at the end of the trial also did not answer this question at baseline. Although the rates for individual and overall risk category did not systematically increase over time, the number of people who reported a high-risk factor at least once increased (table 1) . Treatment groups did not diff er in risk categories at baseline or with time. At baseline, more people in the placebo group had seven of the 15 risk characteristics than in the intervention group, with a maximum excess risk disparity of 18 participants. More people in the vaccine group had the other eight risk characteristics. 5613 (36%) of participants reported a self-assessment of high-risk behaviour at least once during the study. Generally, all other specifi c risk items were far less common than selfreporting of risk. Taken together, the proportion of participants self-classifi ed or assigned to the high-risk group on the basis of specifi c responses rose from 24·1% at entry to 58·2% when including all timepoints in the study (table 1) . The number of HIV infections was similar in baseline high-risk (45) and low-risk participants (46) despite diff erent transmission rates because low-risk participants were more common at baseline. However, most infections (84) were identifi ed in participants who reported high-risk behav iour at baseline or during at least one subsequent visit. An additional 39 HIV infections were diagnosed in participants who initially reported lowrisk (n=28, 14 vaccine and 14 placebo) or medium-risk behaviour (11, fi ve vaccine and six placebo) and subsequently reported at least one period of higher-risk behaviour. The interaction of risk with vaccine effi cacy was signifi cant (p=0·01) between participants reporting highrisk or increased-risk behaviour at least once and those reporting medium risk or low risk throughout the study on a time-varying basis. The vaccine effi cacy estimate for participants who maintained low or medium risk from entry throughout the entire study was 68% (95% CI 34-84, p=0·002). We noted little vaccine eff ect for the high-risk group (vaccine effi cacy 5%, 95% CI -46 to 38).
Although we identifi ed an interaction with risk, the most important risk behaviours for HIV transmission contributed little to the fi ndings of RV 144. For example, although injecting drug use with needle sharing was commonly reported (n=1250 [8·2%]), only fi ve (two vaccine and three placebo) HIV infections were reported in this group. In men reporting sex with men, only 16 HIV infections were noted (eight vaccine and eight placebo).
Vaccine effi cacy fell at each interval (table 2) , with endpoint ascertainment after 12 months, but the interaction of time from fi rst immunisation and outcome was not signifi cant (p=0·36). 1 Nevertheless, the early timepoint effi cacy estimates reported after completion of the vaccine series were substantially greater than those at conclusion of the study-vaccine effi cacy was 54·5% at 6 months and 59·9% at 12 months compared with 29·2% at 42 months. The transmission rate for the placebo group varied modestly from 0·38 per 100 person years in year one to 0·26 per 100 person years in the fi nal year of the investigation. In proportional hazards models that specifi ed the log hazard ratio (vaccine vs placebo) as various smooth functions of time (linear, log-linear, quadratic, and piece-wise cubic polynomials in three or four segments), results were generally consistent with effi cacy, which was most clearly evident early and declined from the second year of follow-up to the end of the study (data not shown). A non-parametric analysis gave a similar result, with early instantaneous hazards effi cacy falling to 0 by 18 months (fi gure 2).
In an additional post-hoc analysis we assessed the relation between timing of infection and viral load. The viral-load endpoint was the average of three samples acquired during the fi rst 6 weeks after serodiagnosis of HIV infection. This endpoint was assessed for acquisition events arising within 600 days of initial vaccination (a period with high effi cacy rate estimates) separately from events reported after this period when effi cacy fell. We detected no diff erence in viral load at any timepoint after infection or in mean early viral load (the co-primary endpoint) between the vaccine and placebo groups when segregated by proximity to vaccination (fi gure 3). The eff ect of vaccine on viral load did not diff er either by baseline risk group or in participants classifi ed as high risk or increased compared with baseline risk.
Discussion
Vaccine effi cacy in the RV 144 trial was unrelated to baseline variables including risk assessment (panel). The risk assessment variable is signifi cant with respect to out come when considered over the course of the study. Further, the effi cacy estimate was highest in the fi rst 6 months after completion of vaccination and fell rapidly.
Risk of infection is a complex, compound estimate of several eff ects but can be simply assessed. 11 Aggregate risk of infection is a function of donor challenge (eg, risk that source is HIV positive, viral load, presence of cofactors including sexually transmitted infections and bleeding), recipient susceptibility (eg, genetically defi ned host characteristics, route of infection, presence of cofactors), and frequency of exposure.
For example, HIV infection in individuals with deletions of CCR5 are uncommon, but if they are exposed frequently the cumulative probability of encountering someone infected with the X4 virus mitigates the protective benefi t of this element of genetic resistance. 12 Furthermore, data from human vaccine and challenge experiments provide convincing evidence that induction of protective immunity can be overcome with a single suffi ciently large challenge. 2 In non-human primate studies, to reproducibly and effi ciently overcome infectious challenge doses and routes seems to need an immune response that is unachievable for the current generation of vaccines. In Vax003, a trial 13 that used AIDSVAX B/E in Thai injecting drug users, the absence of effi cacy might have been because of the stringency of intravenous challenge when compared with the intravaginal and intrarectal routes. This stringency could be because of the circumvention of mucosal barriers and related genetic bottlenecks or the avoidance of vaccineassociated immune responses at mucosal sites. Several lines of evidence [14] [15] [16] suggest that the challenge experienced by injecting drug users is higher in magnitude and genetic diversity than both that faced by non-injectingdrug users and that faced by people infected by a nonintravenous route. Possibly, human vaccines tested in effi cacy trials thus far provided only modest time-sensitive reduction in host susceptibility that was un done by the aggregate transmission challenge intensity.
Vaccine-induced immune responses can reasonably be assumed to be independent of volunteer risk status. The absence of effi cacy in high-risk participants in RV 144 could be because of either the higher challenge per exposure or more frequent exposure, or both, compared with low-risk participants, with participants infected if the threshold exposure occurred when immune responses were inadequate to contain the virus (fi gure 4). By contrast, the population maintaining low risk throughout the study
Panel: Research in context
Systematic review
We systematically searched PubMed with the search terms "vaccine effi cacy", "HIV vaccine trial", and "HIV vaccine clinical study" for HIV vaccine effi cacy trials published in English to identify all randomised controlled trials with behavioural data and a positive outcome. We did not identify any previous studies of HIV vaccines showing effi cacy. There was no restriction on dates of publication.
Interpretation
The effi cacy and benefi t noted in RV 144, which enrolled a population with a low incidence of HIV infection, fell quickly after 12 months and accrued mainly to participants who did not report or perceive themselves to show traditional HIV risk behaviours. Future studies will need to account for participant risk and temporal eff ects. This pox-protein prime boost regimen might show improved effi cacy with extended boosts.
(in whom effi cacy was noted) probably have fewer and possibly less challenging exposures than the high-risk group (fi gure 4). Frequency and route of exposure, and cofactors such as sexually transmitted infections are the basis for consideration of the diff erent degrees of challenge intensity 17, 18 and, correspondingly, the diff erent magnitudes of vaccine-induced immunity needed to achieve protection against HIV infection. Furthermore, we can deduce that vaccine-induced responses must be both high in magnitude and sustained to achieve similar effi cacy in high-intensity challenge populations. Figure 4 shows a modest, time-limited protective immune response (as reported in RV 144) and suggests an additional boost or other augmentation of immune response would improve effi cacy for all risk categories.
A second possibility assumes a more complex model in which diff erent immune responses protect against highrisk and low-risk challenges (eg, responses might occur in diff erent mucosal compartments); the diff er ential decay of these protective responses could explain the early protective eff ect seen in RV 144. Correlation of immune responses induced by the ALVAC-HIV and AIDSVAX B/E regimen to the temporal pattern of protection will be crucial to guide future vaccine development.
Many researchers think that most HIV vaccines under development will not prevent acquisition of HIV infection because they do not stimulate production of neutralising antibodies. 19, 20 A more realistic goal for vaccine development is thought to be induction of T-cell immunity to reduce early viral load and slow disease progression, as has been noted in high-dose challenge studies in nonhuman primates [21] [22] [23] and inferred from studies of elite controllers and long-term non-pro gressors infected with HIV. 24 Despite the apparent absence of neutralising antibodies against primary HIV isolates or broadly neutralising activity, the ALVAC prime and AIDSVAX boost reduced acquisition by 31·2% at 42 months. 1 This regimen did not reduce early viral load even when examined in the period shortly after vaccination when anti-acquisition effi cacy seems highest. This result is consistent with the notion that effi cacy against acquisition requires a diff erent set of immune eff ectors from those needed for reduction in viral load and altered prognosis.
Haynes and colleagues 25 reported that IgG against a conformational glycoprotein 120 V1V2 epitope was inversely correlated with infection in RV 144. These data prompted Barouch and co-workers 7 to look for anti-V2 responses in non-human primates vaccinated with adenovirus type 26 and modifi ed-vaccinia-ankara vectored SIV inserts; anti-(SIV)V2 responses were inversely correlated with infection risk. These fi ndings raise additional hypotheses related to the potential decay of immune responses in the plasma or mucosal compartments.
The value of a vaccine aff ording modest protection in low-challenge-intensity settings as a public health intervention is questionable, but some researchers argue that such a vaccine might be cost eff ective in the Thai setting. 26, 27 Nevertheless, the value of protection against human-to-human transmission of HIV cannot be underestimated. Further elucidation of the nature of protection aff orded in more permissive settings could allow optimisation of vaccine strategies to achieve qualitatively and quantitatively superior vaccines with expanded effi cacy. Our data should be carefully considered in terms of the inherent risks of a post-hoc analysis and are intended to identify subjects deserving further consideration in future effi cacy trials. The questions raised by the data from RV 144 are probably more important to the future of HIV vaccine development than are the primary fi ndings of the trial. Among these issues, the temporal nature of protection and the interaction with risk should be studied in more detail in HIV vaccine trials.
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